Title

Efficacy of tacrolimus in Sjögren's syndrome-associated CNS disease with aquaporin-4 autoantibodies.

Author(s)

Fukuda, Taku; Shiraishi, Hirokazu; Nakamura, Tatsufumi; Tanaka, Keiko; Nakamura, Hideki; Tsujino, Akira; Nishiura, Yoshihiro; Yoshimura, Toshiro; Motomura, Masakatsu; Eguchi, Katsumi

Citation

Journal of neurology, 256(10), 1762-1764; 2009

Issue Date

2009-10

URL

http://hdl.handle.net/10069/24405

© Springer-Verlag 2009; The original publication is available at www.springerlink.com
Efficacy of Tacrolimus in Sjögren's Syndrome-Associated CNS Disease with Aquaporin-4 Autoantibodies

Taku Fukuda, MD;1 Hirokazu Shiraishi, MD;1 Tatsufumi Nakamura, MD;2 Keiko Tanaka, MD;3 Hideki Nakamura, MD;4 Akira Tsujino, MD;1 Yoshihiro Nishiura, MD;1 Toshiro Yoshimura, MD;4 Masakatsu Motomura, MD;1 Katsumi Eguchi, MD1

1First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University
2Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University
3Department of Neurology, Kanazawa Medical University
4School of Health Sciences, Nagasaki University

Corresponding Author: Taku Fukuda

First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, Japan. (postal code: 852-8501)
Phone: +81-95-819-7262; FAX: +81-95-849-7270; e-mail: taku-ngs@umin.ac.jp

Keywords: Tacrolimus, Sjögren's Syndrome, Neuromyelitis Optica
Sirs: We present 2 cases of CNS disease associated with Sjögren's Syndrome (SjS) with anti aquaporin-4 water channel autoantibodies (AQP4-Ab) that were treated successfully with tacrolimus. Tacrolimus is an immunosuppressant that acts as a calcineurin inhibitor and suppresses Th2 cells [1]. Tacrolimus may also act as a neuroprotectant by reducing axonal and myelin damage, as shown in a mouse model of experimental autoimmune encephalomyelitis [2]. SjS is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands. SjS-associated inflammation sometimes spreads into the CNS (CNS-SjS), occasionally mimics relapsing-remitting multiple sclerosis (MS), and inflammation often involves the brain, spinal cord, and optic nerve [3]. Neuromyelitis optica (NMO) is also a relapsing inflammatory disease of the CNS, characterized by severe attacks of optic nerve neuritis and longitudinally extensive transverse myelitis [4]. NMO is distinguished from MS by the presence of AQP4-Ab and differences in the distribution of inflammatory lesions and pathological findings. Combination therapy with a corticosteroid and azathioprine is the current standard treatment for preventing NMO relapse [5]; however, some patients are refractory to it. Approximately 3% of patients with NMO have coexisting SLE or SjS, and CNS-SjS patients with optic nerve neuritis or longitudinal myelitis (conditions called “NMO spectrum disorder”) often present positive for AQP4-Ab [4,6,7]. To our knowledge, this is the first reported assessment of tacrolimus in patients with CNS-SjS with AQP4-Ab. This treatment was approved by the ethical committee of our university, and the patients provided written informed consent.

A 48-year-old female (Case 1, Figure) was admitted with rapidly progressive nausea, hiccups, dysphagia, and drowsiness. MRI revealed T2 hyperintensities of the
hypothalamus bilaterally and of the dorsal medulla oblongata. After 3 courses of intravenous high-dose methylprednisolone (IHMP, 1 g/day for 3 days in 1 course), she recovered completely, except for mild dysphagia. One year after the first attack, she developed limb weakness. Laboratory tests revealed high levels of anti-RO (SS-A) antibodies and positive antinuclear antibody. The Schirmer test and the Saxon test revealed decreased salivary secretion (Table). She was diagnosed with CNS-SjS [8].

She experienced 9 attacks during the entire disease course, and we started treatment with oral tacrolimus during her 9th admission. No recurrent attacks have been observed for 49 months since the start of this treatment.

A 50-year-old female (Case 2) visited our hospital with acute left visual loss and depression. She was diagnosed with retrobulbar optic nerve neuritis, but she rejected steroid therapy and was not admitted to our hospital. One year later, she was sent to our hospital by ambulance due to weakness. Physical examination revealed dysphagia, dysarthria, incomplete tetraplegia, urinary retention, and depression. MRI revealed T2 hyperintensities in the corpus callosum, thalamus, midbrain, and pons. She was diagnosed with CNS-SjS based on SjS criteria (Table), and she was treated with IHMP. Because high doses of oral steroids may exacerbate depression, we started therapy with tacrolimus (3 mg/day) to prevent relapse. No recurrence was observed for 9 months, but she could not continue the therapy due to exacerbation of depression. Two years after withdrawal, she suffered right hemiplegia, and MRI revealed a relapse lesion in the left posterior limb of the internal capsule.

The serum of both patients was positive for AQP4-Ab after the initiation of tacrolimus. Because no recurrences were observed for at least 49 months (Case 1) and 9
months (Case 2), we concluded that tacrolimus is effective in CNS-SjS with AQP4-Ab. Considering the pathological observations that indicate loss of AQP4 with deposition of antibody and compliment in CNS lesions in NMO [9,10], we speculate that tacrolimus may act by suppressing the humoral immunity against AQP4 through Th2 inhibition.
References


Time course of relapse, therapies, symptoms, and images of Case 1. Stars indicate attacks. The thickness of each line represents the severity of any symptom or the dose of drug. Nine attacks had occurred in spite of therapeutic approaches, and no attacks were observed after starting tacrolimus. A: A sagittal fluid-attenuated inversion recovery (FLAIR)-weighted image at onset shows hyperintense lesions in the thalamus, the mammillary bodies and the dorsal portion of the medulla oblongata (arrows). B: A photomicrograph of a labial salivary gland biopsy at the second admission. An aggregate of lymphocytes surrounding a salivary gland. Size bar is 50 µm. C: A sagittal T2-weighted image at the fifth admission shows hyperintense lesions throughout the spinal cord (arrowheads).

IHMP = Intravenous high-dose methylprednisolone (1 g/day for 3 days in 1 course); EDSS = Expanded Disability Status scale.
<table>
<thead>
<tr>
<th>Clinical Features of 2 Cases</th>
<th>Patient</th>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age at onset, sex</strong></td>
<td></td>
<td>48, female</td>
<td>50, female</td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
<td>Japanese</td>
<td>Japanese</td>
</tr>
<tr>
<td><strong>Dry mouth</strong></td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Number of relapses</strong></td>
<td></td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td><strong>MRI findings</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optic lesion</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cerebral lesion</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pontine lesion</td>
<td></td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Medullary lesion</td>
<td></td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Longitudinal cord lesion</td>
<td></td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><strong>Autoantibodies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANA</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SS-A</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SS-B</td>
<td></td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Aquaporin-4</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Diagnostic tests for SjS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schirmer test</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Saxon test</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Salivary gland biopsy</td>
<td></td>
<td>compatible for SjS</td>
<td>not done</td>
</tr>
<tr>
<td>Sialography</td>
<td></td>
<td>not done</td>
<td>compatible for SjS</td>
</tr>
<tr>
<td><strong>CSF findings</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cells /µl</td>
<td></td>
<td>26</td>
<td>37</td>
</tr>
<tr>
<td>MBP [mg/dl, &lt;4.0]</td>
<td></td>
<td>6.2</td>
<td>56.3</td>
</tr>
<tr>
<td>Oligoclonal IgG bands</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Criteria of SjS</td>
<td></td>
<td>fulfilled</td>
<td>fulfilled</td>
</tr>
<tr>
<td>Criteria of NMO</td>
<td></td>
<td>fulfilled</td>
<td>not fulfilled</td>
</tr>
</tbody>
</table>

ANA = antinuclear antibody; MBP = myelin basic protein; NMO = neuromyelitis optica; SjS = Sjögren’s Syndrome
* including first attack